Last reviewed · How we verify

PLD — Competitive Intelligence Brief

PLD (PLD) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated liposomal chemotherapy. Area: Oncology.

marketed Pegylated liposomal chemotherapy DNA (topoisomerase II inhibitor via doxorubicin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PLD (PLD) — AGO Research GmbH. PLD is a pegylated liposomal doxorubicin that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to reduce systemic toxicity while maintaining anti-tumor efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PLD TARGET PLD AGO Research GmbH marketed Pegylated liposomal chemotherapy DNA (topoisomerase II inhibitor via doxorubicin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated liposomal chemotherapy class)

  1. AGO Research GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PLD — Competitive Intelligence Brief. https://druglandscape.com/ci/pld. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: